Clinical Trials and Research Studies
Phase 2
A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Learn MorePhase 1
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
Learn MorePhase 1
Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors
Learn MorePhase 1
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
Learn More